Skip to Main Content

Paper Details

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Ann Oncol
44
2017
Author NameAffiliation
Robert LesurfMcDonnell Genome Institute at Washington University School of Medicine
Obi L GriffithMcDonnell Genome Institute at Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Obi L GriffithSiteman Cancer Center, Washington University School of Medicine
Malachi GriffithMcDonnell Genome Institute at Washington University School of Medicine
Malachi GriffithSiteman Cancer Center, Washington University School of Medicine
Malachi GriffithWashington University School of Medicine
Jasreet HundalMcDonnell Genome Institute at Washington University School of Medicine
Lee TraniMcDonnell Genome Institute at Washington University School of Medicine
Mark A WatsonWashington University School of Medicine
Matthew J EllisMcDonnell Genome Institute at Washington University School of Medicine
Matthew J EllisBaylor College of Medicine
Matthew J EllisWashington University School of Medicine
Vera J SumanMayo Clinic
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
Judy C BougheyMayo Clinic
Kelly K HuntThe University of Texas MD Anderson Cancer Center
Kelly K HuntThe University of Texas MD Anderson Cancer Center
Elaine R MardisInstitute for Genomic Medicine, The Research Institute at Nationwide Children's Hospital
Elaine R MardisThe Ohio State University College of Medicine
Elaine R MardisInstitute for Genomic Medicine, The Research Institute at Nationwide Children's Hospital
Elaine R MardisThe Ohio State University College of Medicine
  • 1 - 22

Datasets

Release 1.2